CRIS Current Research Information System

ZACCHERINI, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.759
EU - Europa 1.962
AS - Asia 1.209
AF - Africa 146
SA - Sud America 8
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.090
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.748
VN - Vietnam 568
IT - Italia 495
GB - Regno Unito 398
SE - Svezia 370
SG - Singapore 235
CN - Cina 214
DE - Germania 202
IN - India 115
IE - Irlanda 92
TG - Togo 76
CH - Svizzera 71
BG - Bulgaria 68
FR - Francia 68
JO - Giordania 39
RU - Federazione Russa 39
UA - Ucraina 34
CI - Costa d'Avorio 33
ZA - Sudafrica 24
FI - Finlandia 22
EE - Estonia 21
ES - Italia 19
IR - Iran 13
HR - Croazia 11
NL - Olanda 11
CA - Canada 10
NG - Nigeria 10
AT - Austria 9
HK - Hong Kong 8
BE - Belgio 7
CZ - Repubblica Ceca 5
LT - Lituania 5
PL - Polonia 5
CL - Cile 4
JP - Giappone 4
RO - Romania 4
NZ - Nuova Zelanda 3
UZ - Uzbekistan 3
AU - Australia 2
ID - Indonesia 2
PH - Filippine 2
VA - Santa Sede (Città del Vaticano) 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BR - Brasile 1
CU - Cuba 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
KE - Kenya 1
MY - Malesia 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
TH - Thailandia 1
TN - Tunisia 1
TR - Turchia 1
Totale 6.090
Salva come PNG Salva come JPEG
Città #
Southend 357
Dong Ket 340
Fairfield 336
Chandler 324
Ashburn 209
Singapore 204
Woodbridge 158
Houston 145
Wilmington 132
Cambridge 121
Seattle 118
Bologna 116
Princeton 112
Ann Arbor 105
Dublin 90
Lomé 76
Sofia 67
Bern 65
Santa Clara 46
Amman 39
New York 38
Abidjan 33
Westminster 33
Berlin 32
Milan 31
Nanjing 29
San Diego 27
Shenyang 26
Padova 23
Turin 21
Beijing 20
Jinan 20
Florence 19
Des Moines 17
Redmond 17
Hebei 16
Helsinki 16
Saint Petersburg 15
Bremen 12
Casalecchio di Reno 12
Rome 12
Medford 11
Modena 11
Paris 11
Abeokuta 10
Changsha 10
Faenza 10
Guangzhou 10
Los Angeles 10
Verona 10
Zhengzhou 10
Fremont 9
Haikou 9
Hyderabad 9
Olalla 9
Amsterdam 8
Ningbo 8
Barcelona 7
Brussels 7
Jacksonville 7
Parma 7
Toronto 7
Hong Kong 6
Lappeenranta 6
Norwalk 6
Reggio Emilia 6
Tianjin 6
Vienna 6
Boardman 5
Frankfurt am Main 5
Gatteo 5
Hangzhou 5
Jiaxing 5
London 5
Redwood City 5
Washington 5
Andover 4
Ardabil 4
Dearborn 4
Falls Church 4
Fusignano 4
Gava 4
Lanzhou 4
Madrid 4
Mülheim 4
Nanchang 4
Prague 4
San Jose 4
Shanghai 4
Taizhou 4
Ancona 3
Auckland 3
Bellinzona 3
Boydton 3
Bühl 3
Castelnuovo Rangone 3
Dallas 3
Edinburgh 3
Esslingen am Neckar 3
Forlì 3
Totale 3.981
Salva come PNG Salva come JPEG
Nome #
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 315
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 297
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 219
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 176
A case of pneumonia and sepsis in cirrhosis as paradigm of the problems in the management of bacterial infections in cirrhosis and of the limitations of current knowledge 155
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 149
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 148
Acute-on-chronic liver failure is a distinct syndrome developing in patients with acute dcompensation of cirrhosis. 139
null 138
Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. 133
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF 130
A case of prolonged cholestatic hepatitis induced by azithromycin in a young woman 126
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 126
The analysis of food intake in patients with cirrhosis waiting for liver transplantation: A neglected step in the nutritional assessment 121
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure 121
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. 120
A Case of Immune-Mediated Liver Injury Induced by Olaparib 120
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications 119
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register 117
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 116
Development and validation of a prognostic score to predict mortality in patients with acute on chronic liver failure. 110
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register 109
Role of human albumin in the management of complications of liver cirrhosis. 106
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 105
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 102
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment 102
QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? 101
Human albumin in the management of complications of liver cirrhosis. 96
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial 96
Hyposplenism as a cause of pneumococcal meningoencephalitis in an adult patient with coeliac disease 94
Disorders of albumin metabolism in liver diseases. 91
Approach and management of dysnatremias in cirrhosis 91
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1-receptor in a rat model of CCl4-induced advanced cirrhosis. 89
Assessing the role of amino acids in systemic inflammation and organ failure in patients with {ACLF} 89
null 88
A web-based group treatment for patients with alcoholic liver diseases at the time of the COVID-19 pandemic 86
Human albumin in the management of complications of cirrhosis. 85
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 85
Pro: The Role of Albumin in Pre–Liver Transplant Management 82
Albumin: Indications in chronic liver disease 77
Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference 75
Management of cirrhotic patients with ascites. 74
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis 74
Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects 70
Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation 69
Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature 66
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology 65
Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease 63
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium 61
null 59
Low haemoglobin level predicts early hospital readmission in patients with cirrhosis and acute decompensation 53
Management of ascites in patients with cirrhosis: An update 52
Albumin administration in internal medicine: A journey between effectiveness and futility 49
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis 46
Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database 44
The Use of Rifaximin in Patients With Cirrhosis 41
Real-word experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-Answer study) 36
The role and indications of albumin in advanced liver disease 33
Prevention of cirrhosis complications: Looking for potential disease modifying agents 31
Living alone as an independent predictor of prolonged length of hospital stay and non-home discharge in older patients 30
Predictors of clinical trajectories of patients with acutely decompensated cirrhosis. An external validation of the PREDICT study 30
Defining aging phenotypes and related outcomes: Clues to recognize frailty in hospitalized older patients 27
Pattern of in-hospital changes in drug use in the older people from 2010 to 2016 25
The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis 24
Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients 19
Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study 18
Long‐term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial 17
Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. 17
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis 15
Need for deprescribing in hospital elderly patients discharged with a limited life expectancy: The REPOSI study 15
Albumin in hospitalized patients with complications of cirrhosis: Not a suit for all seasons 12
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis 11
Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET) 9
Predictors of clinical trajectories in patients admitted for acutely decompensated cirrhosis: An external validation of the PREDICT study 7
Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant 6
Correction to ‘Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF’ [J Hepatol 2020 (72) 688–701] (Journal of Hepatology (2020) 72(4) (688–701), (S0168827819306968), (10.1016/j.jhep.2019.11.009)) 6
Simvastatin plus Rifaximin to prevent ACLF in patients with decompensated cirrhosis. A randomised, double-blind, placebo-controlled, phase-3 trial: the liverhope efficacy trial 5
Predictors of clinical courses in patients wih acutely decompensated cirrhosis. An external validation of the PREDICT study 5
null 4
null 3
null 3
Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis 2
null 1
Totale 6.341
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.108
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.108
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020898 0 0 6 49 80 104 140 154 196 95 47 27
2020/20211.115 126 45 28 28 11 28 37 78 104 37 55 538
2021/20221.390 157 27 63 84 118 80 35 142 56 74 403 151
2022/20231.419 111 220 77 140 94 114 42 95 235 44 120 127
2023/2024679 32 72 53 80 38 132 31 45 19 36 95 46
2024/2025504 107 358 39 0 0 0 0 0 0 0 0 0
Totale 6.341